|
Clinical
Pathways Development for Early Stage Breast Cancer
Assessment
of tumor markers and their deployment in the community: provider and
payer perspectives
Release Date: April
16, 2008
Review Date: January
5, 2009
Expiration Date: December 31, 2009
Target Audience
This activity is intended for physicians, pharmacists, nurses, and case
managers from health plans, hospitals, provider groups, government
programs, and other organizations with an interest in pharmacoeconomics
and health policy development. It may also be useful to other
clinicians and researchers working with public or private payers.
Statement of Need
Recently, the American Society of Clinical Oncology
(ASCO) and the National Comprehensive Cancer Network (NCCN) released
new guidance on the use of breast cancer tumor markers in breast cancer
management strategies. Specifically, they provided new guidance on the
role of molecular diagnostics in breast cancer treatment planning.
These markers can provide a more comprehensive understanding of
underlying tumor biology leading to a more individualized approach in
order to direct therapy. This activity aims to discuss and review the
parameters and methods currently used to risk stratify women with early
breast cancer based on risk for distal recurrence and likelihood of
response to adjuvant therapy in the context of recently released
ASCO/NCCN guidelines and other recent updates. This has implications
toward managed care especially with regard to development of clinical
pathways in order to provide more consistent care patterns leading to
better quality of care.
Educational
Objectives
- Describe some of the evidence behind the NCCN and
ASCO guidelines on the management of early breast cancer related to
tumor markers
- Determine the appropriateness of multi-gene assays
in supporting adjuvant therapy recommendations in early breast cancer
- Create a clinical pathway that addresses the use of
gene expression assays in early breast cancer
Faculty Information and Disclosures
 |
Alan
Wright, MD, MPH (click here for bio)
Principle, The Silverglen Consulting Group, LLC
Sparks, MD |
Dr. Wright has no conflicts of interest to
disclose which directly relate to the content of this activity.
Contributing
Faculty and Disclosures
Sandra
M. Swain, MD, (Chair)
Medical
Director, Washington Cancer Institute
Washington Hospital Center
Washington, DC
Dr. Sandra Swain has no conflicts of interest to
disclose which directly relate to the content of this activity.
David Biggs, MD
Medical Oncology/Hematology Consultants, P.A.
Helen F. Graham Cancer Center
Newark, DE
Dr. David Biggs has no conflicts of interest to disclose
which directly relate to the content of this activity.
Stanley Marks, MD
Deputy Director of Clinical Services UPMC Cancer Center
Chief of Hematology/Oncology, UPMC Shady Side
Clinical Assistant Professor, University of Pittsburgh School of
Medicine
Pittsburgh, PA
Dr. Stanley Marks has no conflicts of interest to
disclose which directly relate to the content of this activity.
Michael Schultz, MD
Director, The Breast Center at St. Joseph's Medical Center
Towson, MD
Dr. Michael Schultz has disclosed that he is on a
speakers' bureau for Genomic Health, Inc.
Fred Smith, MD
Clinical Associate Professor, Georgetown University
Washington, DC
Dr. Fred Smith has disclosed that he is on the speakers'
bureaus for GlaxoSmithKline, Amgen Inc., Genentech, Inc., Genomic
Health, Inc., AstraZeneca, Novartis, and sanofi-aventis.
William Smith, MD
Director, Department of Pathology Suburban Hospital
Bethesda, MD
Dr. William Smith has disclosed that he has received
research support from the National Institute Health.
Winston Wong, PharmD
Associate Vice President, Pharmacy Management
CareFirst BlueCross BlueShield
Baltimore, MD
Dr. Winston Wong has no conflicts of interest to
disclose which directly relate to the content of this activity.
Instructions
To receive a statement of credit, you must:
- Review the full content of the activity and reflect
upon its teachings.
- Complete the questions and evaluation at the end of
the activity. You will have two opportunities to successfully complete
the posttest.
Your statement of credit will be issued immediately
upon successful completion of the posttest and submission of the
evaluation form.
Accreditation Statements
 |
This
activity has been planned and implemented in accordance with the
Essential Areas and Policies of the Accreditation Council for
Continuing Medical Education through the joint sponsorship of Creative
Educational Concepts, Inc. (CEC) and Quest MedEd. CEC is accredited by
the ACCME to provide continuing medical education for physicians. |
CEC designates this educational activity for a
maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
Pharmacy
 |
Creative
Educational Concepts, Inc. (CEC) is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing pharmacy
education. This program has been assigned ACPE # 245-999-08-012-H01-P
will award 1.0 contact hours (.10 CEUs) of continuing pharmacy
education credit. CEC complies with the Criteria for Quality for
continuing education programming. Statements of credit will be issued
automatically on line. |
Nurses
Eastern Kentucky University, the Division of Continuing Education and
Development, is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center's Commission on
Accreditation.
 |
Eastern
Kentucky University, the Division of Continuing Education and
Development, designates this educational activity for 1.0 contact hour.
This activity will provide 1.0 contact hour of nursing credit.
Licensees are required to retain certificates of completion for a
period of five (5) years following the end of their licensure period
and submit certificates to the Board of Nursing only upon request. |
Case Managers
This activity has been approved by the Commission for Case Manager
Certification through 12/31/2009 for up to 1.0 clock hour of continuing
education credit. Approval # 00072302-A201.
Fee
This activity is complimentary.
Disclosure Declaration
It is the policy of CEC and Quest MedEd to ensure independence,
balance, objectivity, scientific rigor, and integrity in their
continuing education activities.
Those involved in the development of this
continuing education activity have made all reasonable efforts to
ensure that information contained herein is accurate in accordance with
the latest available scientific knowledge at the time of accreditation
of this continuing education activity. Information regarding drugs
(e.g., their administration, dosages, contraindications, adverse
reactions, interactions, special warnings, and precautions) and drug
delivery systems is subject to change, however, and the reader is
advised to check the manufacturer's package insert for information
concerning recommended dosage and potential problems or cautions prior
to dispensing or administering the drug or using the drug delivery
systems.
Fair balance is achieved through ongoing and
thorough review of all presentation materials produced by faculty, and
all educational and advertising materials produced by supporting
organizations, prior to educational offerings. Approval of credit for
this continuing education activity does not imply endorsement by CEC or
Quest MedEd of any product or manufacturer identified.
Unlabeled Use Disclosure
This activity may include discussions of products or devices that are
not currently approved for use by the Food and Drug Administration
(FDA), or are currently investigational.
Supporting Organization
This activity is supported by an educational grant
from Genomic Health, Inc.
Software Requirements
|
